Same-day dispatch
Order before 2pm ET — ships from Toronto
COA in every box
Batch-matched third-party certificate
Cold-pack shipped
Temperature-controlled packaging
Purity guarantee
Below spec? Replaced or refunded
Retatrutide
The Next-Generation Triple Agonist — GLP-1 / GIP / Glucagon
Retatrutide (LY3437943) is a novel triple receptor agonist developed by Eli Lilly that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. In Phase 2 clinical trials, retatrutide demonstrated up to 24.2% mean body weight reduction at 48 weeks — the highest weight loss data reported for any pharmacological compound in clinical trials to date. It is currently in Phase 3 trials and represents the most anticipated next-generation metabolic research peptide in North America.
- Triple agonist — GIP, GLP-1 and glucagon receptors
- Largest weight-reduction figures reported in phase 2 obesity trials to date
- The most-searched next-generation metabolic research compound
Vial size
10mg per vial · Lyophilized Powder · Ships same business day from Toronto
Questions about this batch? Text an agent at (905) 993-4764
24.2%
Mean body-weight reduction
48 weeks, 12mg arm, phase 2 trial
3
Receptor targets
GIP / GLP-1 / glucagon triple agonism
98.6%
HPLC purity
Batch TR-RETA-2026-001
Research benefits
Triple Receptor Activity
Simultaneously targets GLP-1, GIP, and glucagon receptors for multi-pathway metabolic research
Phase 2 Data
Up to 24.2% mean body weight reduction observed at 48 weeks (Eli Lilly, NEJM 2023)
Metabolic Research
Studied for effects on insulin sensitivity, adipogenesis, and energy homeostasis
Study findings
Summaries of published research on this compound. Findings are reported for scientific context only and do not constitute claims about this product.
Phase 2 obesity trial
Participants in the highest-dose arm achieved a mean body-weight reduction of 24.2% at 48 weeks versus 2.1% for placebo.
New England Journal of Medicine · 2023
Type 2 diabetes phase 2
Retatrutide produced dose-dependent HbA1c reductions up to ~2.0 percentage points alongside substantial weight reduction.
The Lancet · 2023
Glucagon receptor contribution
Adding glucagon-receptor agonism to incretin agonism increases energy expenditure, a proposed mechanism for the larger weight effect.
Cell Metabolism (review) · 2022
What researchers report
Aggregated, anonymized observations from laboratories ordering this compound. Anecdotal and non-clinical.
Currently the fastest-growing compound in our metabolic research category by order volume.
Researchers commonly run it as a comparator arm against tirzepatide and semaglutide in the same protocol.
Careful dose-titration study designs are the most frequently requested protocol format.
Technical specifications
| Form | Lyophilized Powder |
| Sequence | Triple agonist (GLP-1 / GIP / Glucagon receptors) |
| Molecular Weight | ~4731 g/mol |
| Purity | ≥99% |
| Amount | 10mg per vial |
| Storage | Store at -20°C, protect from light |
| Shelf Life | 24 months (stored at -20°C) |
| COA | COA Available → View Lab Results |
Storage & reconstitution
Store lyophilized vial at -20°C, protected from light.
Reconstitute with bacteriostatic water down the vial wall; do not shake.
Refrigerate at 2–8°C and use within 30 days.
Research background
Retatrutide is a single-molecule triple agonist developed by Eli Lilly, designed to activate three metabolic receptors simultaneously.
Phase 2 clinical trials published in the New England Journal of Medicine (2023) reported the strongest weight reduction data ever recorded for a pharmacological compound.
Phase 3 trials are ongoing and the compound is widely considered the next-generation successor to current GLP-1-only research compounds.
Frequently stacked with
Semaglutide
GLP-1 receptor agonist for metabolic and weight research.
COA AvailableAvailable in 5mg · 10mg · 20mg
Third-party verified
ISO 17025 accredited lab — Batch TR-RETA-2026-001
HPLC Purity
98.6%
Molecular Weight
✓ Verified
Endotoxin (LAL)
<1.0 EU/mg
Heavy Metals (ICP-MS)
✓ Pass
Retatrutide — frequently asked
How does retatrutide differ from tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist; retatrutide adds glucagon-receptor agonism, which research links to increased energy expenditure.
What weight-reduction figures are published?
A phase 2 NEJM trial reported a mean 24.2% body-weight reduction at 48 weeks in the highest-dose arm.
Is it approved for human use?
No. It remains investigational and is supplied here strictly for in-vitro laboratory research.
How fast does it ship?
Orders placed before 2pm ET ship the same business day from Toronto with tracked Canada-wide delivery, typically arriving in 1–3 business days. Cold-pack packaging is used on every shipment.
What if the purity doesn't match the COA?
Every batch is HPLC and mass-spec verified by an ISO 17025 accredited third-party lab, and the batch-matched COA ships with your order. If an independent test comes back below the stated purity, we replace the order or refund it in full.
Is this legal to purchase in Canada?
Yes — these compounds are sold strictly as in-vitro research chemicals for laboratory use. They are not for human or veterinary use, and it is the purchaser's responsibility to comply with applicable federal and provincial regulations.
Ready to add Retatrutide to your research?
≥99% HPLC-verified, endotoxin and heavy metals tested, batch-matched COA included. Ships same business day from Toronto.
Research Use Only Disclaimer
This product is sold exclusively for in-vitro research and laboratory use only. It is NOT intended for human or veterinary use, consumption, injection, or any clinical application. This product has not been evaluated by Health Canada, the FDA, or any other regulatory authority for safety or efficacy in humans or animals. Trinity makes no medical claims regarding this compound. Researchers must comply with all applicable federal, provincial/state, and local laws regarding the purchase, storage, and use of research compounds. By purchasing this product, you confirm you are a qualified researcher or licensed professional acting within the bounds of applicable law.